Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase I/II
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2018 Planned primary completion date changed from 1 Aug 2017 to 31 Aug 2019.
- 12 Apr 2018 Planned number of patients changed from 72 to 93.
- 12 Apr 2018 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.